In the 1990s, scientists at The Institute of Cancer Research identified the breast cancer 2 gene, BRCA2, and mutations in it that greatly increase the carrier’s risk of developing breast cancer and ...

A Mayo Clinic-led team of researchers is solving one of the most frustrating aspects of genetic cancer screening — results that give zero guidance to patients on whether they are at elevated risk.

Approximately one in 400 people, and one in 100 diagnosed with breast cancer, have a BRCA2 mutation, Couch said. People who have a BRCA2 loss-of-function pathogenic mutation have a 69% lifetime ...

While some mutations in the BRCA2 gene clearly indicate risks for breast and prostate cancer, thousands of less-common variations have confounded doctors and left anxious patients without guidance ...

We observed that as expected we had a higher rate of HRD alterations, so BRCA1 and BRCA2 alterations in triple-negative breast cancer, while we had a lower rate in hormone receptor-positive ...

Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...

Olaparib is available on the NHS. It is a possible treatment for HER2-negative, locally advanced or metastatic breast cancer with inherited (germline) BRCA1 or BRCA2 mutations in adults who have had: ...